SCHEMBL19459868

SCHEMBL19459868

CC(C)NC(=O)C(=O)CC(=O)c1ccncc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 5/20 0.51
▸ HPGD P15428 3/20 0.51
▸ PLOD2 O00469 2/20 0.51
▸ PLOD3 O60568 2/20 0.51
▸ PLOD1 Q02809 2/20 0.51
▸ CYP1A2 P05177 2/20 0.51
▸ CYP2D6 P10635 2/20 0.51
▸ CYP2C19 P33261 2/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ HIF1A Q16665 1/20 0.51
▸ MAOA P21397 1/20 0.47
▸ MAOB P27338 1/20 0.47
▸ PTGS2 P35354 1/20 0.47
▸ LMNA P02545 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.42
▸ MPO P05164 1/20 0.42
▸ ADORA3 P0DMS8 1/20 0.42
▸ CYP2A6 P11509 1/20 0.42
▸ NAMPT P43490 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19465019 0.81 PLOD2 (0.56) CYP3A4HPGDPLOD2PLOD3PLOD1
SCHEMBL10948430 0.75 PLOD2 (0.83) CYP3A4HPGDPLOD2PLOD3PLOD1
SCHEMBL31466251 0.75 PLOD2 (0.58) CYP3A4HPGDPLOD2PLOD3PLOD1
SCHEMBL2587127 0.75 ALDH1A1 (0.53) CYP3A4HPGDPLOD2PLOD3PLOD1
SCHEMBL17179998 0.74 PLOD2 (0.68) CYP3A4HPGDPLOD2PLOD3PLOD1
SCHEMBL1106938 0.74 MAOA (0.67) CYP3A4HPGDCYP1A2CYP2D6CYP2C19
SCHEMBL17788483 0.74 ALDH1A1 (0.52) CYP3A4HPGDPLOD2PLOD3PLOD1
SCHEMBL1062957 0.74 PLOD2 (0.56) CYP3A4HPGDPLOD2PLOD3PLOD1
SCHEMBL1919299 0.73 PLOD2 (0.60) CYP3A4HPGDPLOD2PLOD3PLOD1
Bromide SCHEMBL7372571 0.73 MAOA (0.65) CYP3A4HPGDCYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9951058-B2 Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing the same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D (BE) 2018-04-24 — — US disclosed
US-9790197-B2 Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing the same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D (BE) 2017-10-17 — — US disclosed
US-9790197-B2 Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing the same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D (BE) 2017-10-17 — — US disclosed
Send feedback